Navigation Links
Positive Glufosfamide Results From a Phase 2 Clinical Trial Presented at European Cancer Conference (ECCO)
Date:9/26/2007

months. In addition, 11 of 28 patients (39%) experienced stable disease (duration 1.2+ to 12.6+ months). Objective response was assessed radiologically after every two cycles (8 weeks) of therapy. A partial response is characterized as a decrease in size by 30% of the sum of the longest diameters of target lesions, the absence of progression of all non-target lesions and no new lesions.

Grade 3 and 4 neutropenia occurred in 8 (28%) and 15 (52%) patients. Grade 3 and 4 thrombocytopenia occurred in 8 (28%) and 2 (7%) patients. Five patients (18%) had a glufosfamide-related serious adverse event (SAE), which included renal tubular acidosis (RTA) with renal failure (2 patients), RTA alone, vomiting or nausea. Three patients died from an SAE unrelated to glufosfamide. Another patient developed an SAE of renal failure after hypotension associated with pulmonary embolus. The creatinine clearance (CrCL) fell below 60 mL/min in 10 of 27 (37%) patients with CrCL greater than or equal to 60 at baseline.

These data indicate that glufosfamide plus gemcitabine may benefit patients with chemotherapy nave pancreatic adenocarcinoma. Hematologic and renal toxicity may be greater than would be expected with either agent alone although the small numbers preclude definitive conclusions. No unanticipated adverse events based on previous experience with glufosfamide were observed.

The Phase 2 poster is available on the Threshold website at http://investor.thresholdpharm.com/calendar.cfm.

About Glufosfamide

Glufosfamide combines the active part of ifosfamide, a member of a widely used class of chemotherapy drugs known as "alkylators", with a glucose molecule. Because of its glucose component and a tumor cell's increased need for glucose, glufosfamide may be preferentially transported into tumors compared to most normal tissues. Inside cells, the linkage between glucose and the alkylat
'/>"/>

SOURCE Threshold Pharmaceuticals, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
2. Positive Aggrastat Results Featured in the Journal of the American College of Cardiology
3. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
4. Protox Announces Positive Clinical Data from Prostate Cancer Study
5. AM-Pharma Announces Positive Results of Phase IIa Clinical Trial with Alkaline Phosphatase For Ulcerative Colitis
6. Cougar Biotechnology Announces Presentation of Positive CB7630 Clinical Data at ESMO Conference
7. TransPharma Medical Announces Positive Results of Phase I Clinical Trials for Transdermal Delivery of hPTH (1-34) for Osteoporosis Treatment
8. Positive ZIO-201 Interim Phase II Sarcoma Data Presented at European Society for Medical Oncology
9. Cosmo Pharmaceuticals Reports Positive Preliminary Phase II/III Data with Rifamycin MMX in Infectious Diarrhea
10. Portola Pharmaceuticals Announces Positive Phase II EXPERT Results and Additional Oral and Poster Presentations at the XXI Congress of the International Society on Thrombosis and Haemostasis (ISTH)
11. Chi-Med Announces Positive Phase II Proof-of-Concept Data for HMPL-004 in Ulcerative Colitis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... May 22, 2015 The leading companies ... billion global cardiac rhythm management device market dominate ... that Medtronic, St. Jude Medical, Boston Scientific and ... this market segment. The healthcare market research publisher,s ... uses 2015 as a base year, providing forecasts ...
(Date:5/22/2015)...  RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX), a clinical-stage drug ... today announced that J.J. Finkelstein , chief executive ... overview at two upcoming investor conferences. ... Annual Microcap Conference on Thursday May 28, 2015 ... 11:00 am EDT.  A webcast will be available at ...
(Date:5/22/2015)... KING OF PRUSSIA, Pa. , May 22, 2015 /PRNewswire/ ... CSL Behring its 2015 Corporate Leadership Award as recognition ... and improving the care of the bleeding disorders community.  The ... Managing Director, CSL Limited, during the NHF Annual Spring Soiree ... 21. "The National Hemophilia Foundation is dedicated to ...
Breaking Medicine Technology:Kalorama: Top Companies Dominate Cardiac Defibrillator Market 2Kalorama: Top Companies Dominate Cardiac Defibrillator Market 3Kalorama: Top Companies Dominate Cardiac Defibrillator Market 4RegeneRx to Present at 2 Investor Conferences 2RegeneRx to Present at 2 Investor Conferences 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 2National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 3National Hemophilia Foundation Honors CSL Behring with Corporate Leadership Award 4
... VisionCare Ophthalmic Technologies, Inc., a developer of ... macular degeneration (AMD), today announced upcoming scientific and ... investigational telescope implant is the first medical device ... FDA Ophthalmic Devices Advisory Panel for End-Stage AMD, ...
... 20 Pulmo BioTech Inc. (OTC Bulletin Board: PLMO; ... into a non-binding letter of intent with BioTechnology Consulting ... Product Candidate PulmoBind(TM) for development work, clinical trials and ... very pleased to have signed a non-binding LOI with ...
Cached Medicine Technology:VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 2VisionCare Implantable Telescope Technology Presentations Featured at Upcoming American Academy of Ophthalmology and Ophthalmology Innovation Summit Meetings 3Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 2Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 3Pulmo BioTech Inc. Announces Letter of Intent Regarding Proposed License of its Pulmonary Vascular Diagnostic Product Candidate PulmoBind(TM) 4
(Date:5/24/2015)... 24, 2015 EnviroLeather™ by LDI, ... Plus” – a classic, rugged leather grain with ... difficult stains, including ink, to be easily removed. ... suitable for corporate, healthcare, hospitality and education environments. ... EnviroLeather’s goal of developing products that are more ...
(Date:5/24/2015)... Arizona (PRWEB) May 24, 2015 ... former Millennial Media strategy executive Jay Krihak as ... Medicx looks to ramp up its expertise and ... of the Pharmaceutical and Health sectors. , Krihak ... tech executive. Most recently, Krihak led sales planning ...
(Date:5/23/2015)... Washington, D.C. (PRWEB) May 23, 2015 ... demonstration of powers of a youngster's yogic power learned ... by Sri Nithyananda Swami in Bangalore, India. , Yogamaatha, ... of more than 50 high profile professionals attending the ... D.C. by reading fluently -- blindfolded. , In ...
(Date:5/23/2015)... On May 16, the team at ... a 5k mud obstacle run that raised funds for multiple ... worldwide, and the reason we participated was to support people ... of Farrell’s eXtreme Bodyshaping. “One-hundred percent of the funds raised ... event was not only attended by eXtreme Bodyshaping staff, but ...
(Date:5/23/2015)... CA (PRWEB) May 23, 2015 Add High-Quality ... from Pixel Film Studios. , It's as simple as dragging ... utilizing the included tool for full effect. , Including ... on high-dynamic range 5k sensors making this the ultimate bundle ... prismatic flares included in this package are movie files designed ...
Breaking Medicine News(10 mins):Health News:EnviroLeather By LDI Launches "InkGard Plus" - Stain Resistant Faux Leather 2Health News:Medicx Media Solutions Expands Executive Team 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 2Health News:Nine-Year-Old Reads Blindfolded at Business Advocacy Summit 3Health News:Farrell’s eXtreme Bodyshaping Team Runs through the Muck for MS 2Health News:Developers at Pixel Film Studios Release ProFlare 5K Prism for Final Cut Pro X. 2
... Over ... their subscribers and readers demand for more alkaline and organic food…, , ... (PRWEB) June 14, 2010 -- TheAlkalineDiet.org has just ... products from all over the world. Since the launch of the website in November 2009, ...
... patients who directly confronted the stress of the Second Lebanon ... with the situation by focusing on feelings. This has been ... the University of Haifa, the Technion-Israel Institute of Technology and ... sclerosis to date, it is important to uncover all the ...
... recommended A1c blood test cutoff didn,t accurately diagnose elderly ... -- Despite its endorsement last year by the American ... 2 diabetes, new research out of Singapore suggests that ... the disease among elderly Asians. , The American Diabetes ...
... ... Horizon Healthcare Services, Inc. to Put Evidence-Based Medicine into Practice with Via Oncology Pathways ... Pittsburgh ... will continue to improve as a result of wider application of Via Oncology™ Pathways, ...
... ... ,Camera to data toggle application revolutionizes any Windows Mobile Device with Camera and replaces any ... ... of the Kodak roll film camera in 1888, engineers, inspectors and professionals have used a ...
... ... The Verdin Company announced today it has acquired ... a leader in manufacturing architectural site furnishings. The Verdin Company, ... installer of clocks, bells, carillons, bell and clock towers, glockenspiels, and ...
Cached Medicine News:Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 2Health News:Official Alkaline Diet Site Launches Organic Food Store for Healthy Living And Natural Weight Loss 3Health News:Can multiple sclerosis attacks be minimized in a war zone? 2Health News:Age, Race May Affect Type 2 Diabetes Screening Results 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 2Health News:Hematology-Oncology Associates of Northern New Jersey (HOANNJ) Joins Effort to Improve Cancer Care with Via Oncology™ Pathways 3Health News:Mobile and Patented: DATA-TO-CAMERA TOGGLE on handheld device replaces old camera and clipboard approach everywhere! Beats IPAD to camera punch too..... 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 2Health News:The Verdin Company Acquires Canterbury International, an industry leader in architectural site furnishings for over 50 years 3
... The T-ACE II is ... component extractor for the,standardized processing ... Good Manufacturing Process.,The device is ... all common bag systems of ...
The Plasma Extractor is used to express blood components from collection containers. The spring-loaded front panel exerts pressure on the collection container causing the fluid to transfer until cont...
... a positive-displacement, continuously adjustable, ... to simplify multiple dispensing ... DistriTip syringes. DistriTips (DT) ... level indicators. Three models ...
... The Repeater Pipette* provides quick, convenient, ... procedures. Eppendorf Combitips have a polyethylene ... them ideal for use with most ... Product features: Five separate volumes can ...
Medicine Products: